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Abstract
Leishmania infantum is an etiological agent of the life-threatening visceral form of leishmani-
asis. Liposomal amphotericin B (AmB) followed by a short administration of miltefosine (MF)
is a drug combination effective for treating visceral leishmaniasis in endemic regions of
India. Resistance to MF can be due to point mutations in the miltefosine transporter (MT).
Here we show that mutations in MT are also observed in Leishmania AmB-resistant
mutants. The MF-induced MT mutations, but not the AmB induced mutations in MT, alter
the translocation/uptake of MF. Moreover, mutations in the MT selected by AmB or MF have
a major impact on lipid species that is linked to cross-resistance between both drugs. These
alterations include changes of specific phospholipids, some of which are enriched with
cyclopropanated fatty acids, as well as an increase in inositolphosphoceramide species.
Collectively these results provide evidence of the risk of cross-resistance emergence
derived from current AmB-MF sequential or co-treatments for visceral leishmaniasis.
Author Summary
Miltefosine and amphotericin B are two leading molecules in the fight against the vector-
borne disease Leishmaniasis. We demonstrate here that different point mutations in a P-
type ATPase could play an important role in resistance, not only to miltefosine, but also to
amphotericin B. Furthermore, macrophage-infecting amastigotes that are resistant to one
drug are cross-resistant to the other one. Our experimental findings demonstrate that one
of the mechanisms driving miltefosine and amphotericin B resistance in Leishmania para-
sites involve major changes in a number of lipid species. In addition, we experimentally
show that different mutations in the P-type ATPase participate in resistance against these
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005171 December 2, 2016 1 / 20
a11111
OPENACCESS
Citation: Fernandez-Prada C, Vincent IM,
Brotherton M-C, Roberts M, Roy G, Rivas L, et al.
(2016) Different Mutations in a P-type ATPase
Transporter in Leishmania Parasites are Associated
with Cross-resistance to Two Leading Drugs by
Distinct Mechanisms. PLoS Negl Trop Dis 10(12):
e0005171. doi:10.1371/journal.pntd.0005171
Editor: Louis Maes, University of Antwerp,
BELGIUM
Received: August 29, 2016
Accepted: November 8, 2016
Published: December 2, 2016
Copyright: © 2016 Fernandez-Prada et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The sequence data
for L. infantum 263 AMB1000.1 is available at the
EMBL European Nucleotide Archive (http://www.
ebi.ac.uk/ena) under study accession ERP001815.
Funding: Work in TKS’s lab is supported by the
Wellcome Trust grant 093228 and European
Community’s Seventh Framework Programme
under grant agreement No. 602773 (Project
KINDRED). LR is supported by FEDER ISCIII PI12-
02706 and RETICS (Ricet RD12/0018/0007). MO
holds a Canada research chair in antimicrobial
two leading leishmanicidal agents with mechanistic differences. Miltefosine-induced
mutations cause a defect in miltefosine uptake, but this mechanism of resistance is not
observed for the amphotericin B-induced mutations. These results point to profound clin-
ical implications as combination therapy involving these two drugs is being promoted for
the treatment of visceral Leishmaniasis.
Introduction
Protozoan parasites belonging to the Leishmania genus cause several vector-borne diseases
collectively referred as leishmaniases. Currently, Leishmania species threaten ca. 350 million
people in 88 countries worldwide [1]. Control measures primarily rely on prevention and che-
motherapy (reviewed in [2]). The old-fashioned and toxic antimonial derivatives top the short
list of registered compounds against Leishmania spp. In addition to their toxicity, pentavalent
antimonials require long treatment schedules and are associated with resistance [1, 3].
Amphotericin B (AmB) liposomal formulations were introduced for the treatment of visceral
leishmaniasis in antimonial-non-responsive regions of Bihar (India) [4]. Clinical resistance to
AmB is rare [5] but a recent study in India has reported a L. donovani field strain resistant to
AmB [6]. Another leishmanicidal drug introduced in the early 21st century is the alkyl-phos-
pholipid analogue miltefosine (MF). It was the first effective oral drug showing high cure rates
in the treatment of several forms of leishmaniasis. However, since its registration in 2002, it
has had increasing relapse rates and the emergence of drug resistance strains [7, 8].
None of these drugs have a well-defined mode of action against Leishmania spp. and pri-
mary protein drug targets are unlikely [9]. AmB seems to generate channel-like pores spanning
the lipid bilayer by binding preferentially to ergosterol within the membranes, hence leading
to cells death [10, 11]. Several reports suggest that MF is able to target lipid metabolism, in
addition to glycosylphosphatidylinositol (GPI) anchor biosynthesis and signal transduction
[12]. MF-treated parasites show an increase in phosphatidylethanolamine (PE) and lyso-phos-
phatidylcholine (PC) content in their membrane [13].
Both MF and AmB affect lipids in cellular membranes [11, 14], and resistance mechanisms
seem to involve changes in lipids. AmB-resistance in Leishmania mainly implies changes in
cell membrane fluidity (reviewed in [15]). The sterol content of L. donovani AmB-resistant
promastigotes analysed by gas chromatography coupled to mass spectrometry (GC-MS)
revealed an enrichment in cholesta-5,7,24-trien-3β-ol [11], which suggests a more fluid cellular
surface. On the other hand, resistance to MF primarily implies a transport defect with inactiva-
tion of the P-type ATPase miltefosine transporter (MT), or of its regulatory subunit LdRos3,
causing a decrease in the uptake of lyso-phospholipids [16–18]. A recent study has reported
changes to the metabolism of lipids in L. infantum MF-resistant parasites [19], further support-
ing that MF influences fatty acid and/or sterol metabolism [20].
We report here that the MT is mutated in both MF and AmB resistant mutants. The muta-
tions are associated with cross-resistance and correlate with major changes in membrane lipid
composition. These modifications in lipid composition were analysed through a range of lipi-
domic approaches and we show that different mutations in MT trigger changes in lipid com-
positions leading to both MF and AmB resistance. These findings are of potential clinical
relevance as the sequential treatment of liposomal AmB followed by a short 7-days administra-
tion of MF has been used against visceral leishmaniasis in India [21,22].
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Material and Methods
Leishmania cultures
The Leishmania infantum (MHOM/MA/67/ITMAP-263) wild-type strain (Ldi263 wt) and the
in vitro generated resistant mutants AmB1000.1 and MF200.5 [23, 24], which are respectively
resistant to 1000 nM of AmB and 200 μM MF, were grown in SDM-79 medium at 25˚C sup-
plemented with 10% fetal bovine serum, 5 μg/mL of haemin at pH 7.0 with either 200 μM of
MF (Miltefosine, Cayman Chem.) or 1 μM AmB (Amphotericin B solution, Sigma) for the
mutant strains, and 40 μg/mL G418 (Geneticin, Gibco-BRL) for the episomal overexpressors.
EC50 values were calculated based on dose-response curves analysed by non-linear regression
with GraphPad Prism 5.01 software. An average of at least three independent biological repli-
cates was performed for each determination. Statistical significance between the mock-trans-
fected wild-type and the tested strains was evaluated by unpaired two-tailed t test.
Whole genome sequencing for AmB1000.1 strain
Genomic DNA was prepared from a mid-log phase clonal culture of L. infantum 263
AmB1000.1. A paired-ends sequencing library was prepared with the Nextera DNA sample
prep kit and sequenced on an Illumina MiSeq platform with 250-nucleotide paired-ends reads.
An average genome coverage of over 50-fold was obtained for the mutant. This approach
allowed us to identify point mutations when comparing with the reference genome sequence
of L. infantum JPCM5 (TriTrypDB version 8.0) [25] and L. infantum 263 wt [26]. Sequence
reads were aligned to the L. infantum JPCM5 genome using the software bwa-mem [27]. The
maximum number of mismatches was 4, the seed length was 32 and 2 mismatches were
allowed within the seed. Read duplicates were marked using Picard (http://broadinstitute.
github.io/picard) and we applied GATK for indel realignment and snp and indel discovery
[28, 29] in L. infantum 263 AmB1000.1. PCR amplification and conventional DNA sequencing
verified all putative point mutations detected by whole genome sequencing. Copy numbers
variations were derived from read depth coverage by comparing the coverage of uniquely
mapped reads between L. infantum 263 AMB1000.1 and L. infantum 263 wt along small non-
overlapping genomic windows (5 kb) for the 36 chromosomes (normalized to the total num-
ber of uniquely-mapped reads for each strain) [30]. Several python and bash scripts were cre-
ated to further analyze the data. The sequence data for L. infantum 263 AmB1000.1 is available
at the EMBL European Nucleotide Archive (http://www.ebi.ac.uk/ena) under study accession
ERP001815 and sample accession ERS176091.
DNA constructs and transfection
The LinJ.13.1590 and LinJ.16.1240 genes of L. infantum (LinJ10_V5.0) were amplified from
genomic DNA using compatible primer pairs and PCR fragments were ligated into pGEM T-
easy (Promega, Madison, WI, USA) for confirming the quality of the insert by standard
sequencing, and then cloned in the Leishmania expression vector pSP72αNeoα [31], which
contains the gene neomycin phosphotransferase (NEO) as selectable marker in Leishmania. A
total of 20 μg of plasmid DNA for episomal expression, either the empty vector (mock) or car-
rying the genes of interest, were transfected into Leishmania promastigotes by electroporation
as described previously [31]. Selection was achieved in the presence of 40 μg/mL G418.
Miltefosine uptake
Miltefosine uptake was performed as described previously [19]. Briefly, Leishmania parasites
were incubated in the presence of MT-11C-BODIPY [32] for 1 h. Then fluorescence emission
Miltefosine Transporter in Amphotericin B Resistance
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was recorded and used to calculate the moles of internalized MF analogue. An average of three
independent biological replicates run in triplicate was performed. Statistical significance
between the mock-transfected wild-type and the tested strains was evaluated by unpaired two-
tailed t test.
Macrophage infections
As previously published [9] macrophage infections and drug susceptibility assays were per-
formed as following: PMA-differentiated THP-1 macrophages were infected with stationary-
phase parasites at a ratio of 18:1, for 2 h at 37˚C in a 5% CO2 atmosphere. Cells were main-
tained in drug-free medium for 48 h after which infected cells were either left untreated or
treated for 96 h at 37˚C. The number of infecting amastigotes per 100 macrophages was deter-
mined by examination of 100 macrophages per assay in two independent experiments run in
triplicate, which allowed for calculating the parasitic index (PIdx) as the percentage of infected
cells multiplied by the mean number of parasites per cell. Statistical significance between the
mock-transfected wild-type and the tested strains was evaluated by unpaired two-tailed t test.
Lipid extraction
Total lipids were extracted using a modified Bligh and Dyer method. Briefly, cells were washed
with PBS, suspended in 100 μL PBS and transferred to a glass tube, 375 μL of 1:2 (v/v) CHCl3:
MeOH added and vortexed. The samples were agitated vigorously for a further 10–15 min.
The samples were now made biphasic by the addition of 125 μL of CHCl3, vortex and then
125 μL of H2O and vortexed again and centrifuged at 1000 g at RT for 5 min. The lower phase
was transferred to a new glass vial and dried under nitrogen and stored at 4˚C.
Electrospray-mass spectrometry analysis
Total lipid extracts were dissolved in 15 μL of CHCl3: MeOH (1:2) and 15 μL of acetonitrile:
iso-propanol: water (6:7:2) and analysed with a AB Sciex 4000 QTrap, a triple quadrupole mass
spectrometer equipped with a nanoelectrospray source. Samples were delivered using a Nano-
mate interface in direct infusion mode (~125 nL/min). The lipid extracts were analysed in both
positive and negative ion modes using a capillary voltage of 1.25 kV. MS/MS scanning (daugh-
ter, precursor and neutral loss scans) were performed using nitrogen as the collision gas with
collision energies between 35–90 V. Each spectrum encompasses at least 50 repetitive scans.
Tandem mass spectra (MS/MS) were obtained with collision energies as previously
described [33], phosphatidylinositol (PI)/ inositol-phosphoceramide (IPC) in negative ion
mode, parent-ion scanning of m/z 241 (PI 32:0 internal standard); 35-65V, PE in negative ion
mode, parent-ion scanning of m/z 196 (PE 28:0 internal standard); 20-35V, C19Δ parent ion
mode scanning m/z 295. MS/MS daughter ion scanning was performed with collision energies
between 35-90V. Assignment of phospholipid species is based upon a combination of survey,
daughter, precursor and neutral loss scans, as well as previous assignments [33, 34]. The iden-
tity of phospholipid peaks was verified using the LIPID MAPS: Nature Lipidomics Gateway
(www.lipidmaps.org). Accurate mass spectra were also acquired (± 2 ppm) on an Orbitrap MS
to assist definitive assignment of C19Δ fatty acid containing PE species.
Inositol analysis
For inositol analysis, a fixed number of cells from different strains were collected and lipids
extracted as above. An internal standard of D6-myo-inositol was added to samples prior to
hydrolysis by a strong acid (6M HCl, o/n at 110˚C), derivatised with trimethylsilyl ethers and
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analysed by GC-MS, as published elsewhere [35]. Myo-inositol was quantified and the mean and
standard deviations of three separate analyses were determined for IPC and PI inositol quantifi-
cation, lipid samples underwent base hydrolysis 500 μL of concentrated ammonia and 50% pro-
pan-1-ol (1:1), followed by incubation for at least 5 h at 50˚C. Upon drying under nitrogen and
removal of traces of ammonia with 2 rounds of H20/MeOH evaporation, the modified Bligh and
Dyer method as described above was conducted to separate the IPC in the organic phase and
inositol-phospho-glycerol derived from the PI, which had been deacylated into the aqueous
phase. These two phases were dried down and processed for inositol content as described above.
Identification and quantification of fatty acids
Full characterisation and quantification of the fatty acids by conversion to the corresponding
fatty acid methyl esters (FAME) followed by GC-MS analysis was performed as previously
described [36]. Briefly, mid-log cell-lines were spun down and triplicate aliquots equivalent to
108 cells were transferred to 2 mL glass vessels and spiked with an internal standard fatty acid
C17:0 (20 μL 1 mM) and dried under nitrogen. Fatty acids were released by base hydrolysis
using 500 μL of concentrated ammonia and 50% propan-1-ol (1:1), followed by incubation for
at least 5 h at 50˚C. After cooling, the samples were evaporated to dryness with nitrogen and
dried twice more from 200 μL of H2O/MeOH (1:1) to remove all traces of ammonia. The pro-
tonated fatty acids were extracted by partitioning between 500 μL of 20 mM HCl and 500 μL of
ether, the aqueous phase is re-extracted with fresh ether (500 μL) and the combined ether
phases were dried under nitrogen in a glass tube.
The fatty acids were converted to FAME by adding diazomethane (3 x 20 μL aliquots) to
the dried residue on ice. After 30 min the samples were allowed to warm to RT and left to evap-
orate to dryness in a fume hood. The FAME products were dissolved in 10–20 μL dichloro-
methane and analysed by GC-MS by injection of 1–2 μL on a Agilent Technologies (GC-
6890N, MS detector-5973) with a ZB-5 column (30 M x 25 mm x 25mm, Phenomenex), with a
temperature program at 70˚C for 10 min followed by a rising gradient to 220˚C at 5˚C /min
and held at 220˚C for a further 15 min. Mass spectra were acquired from 50–500 amu. The
identity of FAMEs was carried out by comparison of the retention time and fragmentation pat-
tern with a bacterial FAME standard that contains both C17Δ and C19Δ (Supelco).
Sterol analysis
Lipid extractions of triplicate aliquots equivalent to 108 cells were transferred to 2 mL glass ves-
sels and dried down. The lipid extracts were dissolved in 20 μL dichloromethane and analysed
by GC-MS by injection of 1 μL on a Agilent Technologies (GC-6890N, MS detector-5973),
injector at 270˚C with a ZB-50 column (15 mm x 32 mm id x 0.5 mm thickness, Phenomenex),
injector at 270˚C with a temperature program at 100˚C for 1 min followed by a gradient to
200˚C at 8˚C /min and held at 200˚C for a further 2 min followed by a second gradient to
300˚C at 3˚C /min and held for a further 15 min. Mass spectra were acquired from 50–550
atomic mass units. The identity of sterols was carried out by comparison of the retention time
and fragmentation pattern with a range of standards purchased from Sigma and Materya.
Results
Whole genome sequencing of L. infantum aAmB1000.1 reveals a point
mutation in the miltefosine transporter MT
The in-vitro selected resistant mutant L. infantum AmB1000.1 was previously characterized by
means of a large-scale proteomic study [23], and here its genome was sequenced using paired-
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ends Illumina sequencing and compared to the one of its parent line. An average of 50-fold
genome coverage was obtained for both the wild-type and the mutant. Read depth coverage
analysis did not identify specific gene amplification or deletion in the mutant (S1 Dataset),
although aneuploidy was observed for 6 chromosomes (S1 Table), a phenomenon often
observed in drug resistant mutants [18, 37–39]. A search for point mutations revealed 18
homozygous single nucleotide polymorphisms (SNPs) in the AmB1000.1 mutant (S2 Table), 3
of which occurred within coding sequences (CDS) and caused an amino acid change (S2 Data-
set). These occurred within the MT ORF (LinJ.13.1590), in gene LinJ.16.1240 coding for a
hypothetical transmembrane protein and in LinJ.35.0520, a large proteophosphoglycan pro-
tein made up of a short 88-times repeated sequence which is often found mutated in our vari-
ous sequencing screens. The latter gene was not studied further. The SNPs in MT and
LinJ.16.1240 were confirmed by sequencing PCR fragments derived from AmB1000.1. An
additional 470 heterozygous SNPs were also detected in the genome of AmB1000.1, 85 of them
being in CDS and non-synonymous (S2 Table). Interestingly none of these occurred within
the ORF coding for the regulatory subunit Ros3 that is necessary for the expression of a func-
tional MT translocation machinery [17] (S3 Dataset).
Mutations of the MT gene in AmB1000.1 modulate AmB resistance and
is associated with cross-resistance to MF
We next tested whether mutations in the MT or the LinJ.16.1240 gene detected in AmB1000.1
directly contributed to AmB resistance. We also included the previously characterized MF
resistant mutant L. infantum MF200.5 [24] with a known mutation in MT. Targeted sequenc-
ing of the MT in L. infantum MF200.5 confirmed the previously described G565R mutation,
but also revealed two new mutations located at the very beginning of the gene and within a
conserved domain (S1 Fig). The emergence of these new mutations is probably due to continu-
ous culturing of the L. infantum MF200.5 mutant in the presence of high MF concentrations.
The mutants AmB1000.1 and MF200.5 were highly resistant to AmB (Fig 1A and 1C) and MF
respectively (Fig 1B and 1C). Remarkably, both mutants also showed MF/AmB cross-resis-
tance, with mutant AmB1000.1 being 3.7 fold less sensitive to MF than wild-type parasites (Fig
1B and 1C) and MF200.5 being 2.7-fold cross-resistant to AmB (Fig 1A and 1C).
Transfection of the wild-type MT gene as part of an episomal vector in the L. infantum
AmB1000.1 and MF200.5 lines abolished, as expected and previously described [17, 38], MF
resistance in MF200.5 and interestingly in AmB1000.1 compared to mock-transfected para-
sites (Fig 1C). Surprisingly, transfection of the MT gene also reduced the AmB resistance to
wild-type levels in the case of MF200.5 and partially reverted resistance to AmB by 4-fold for
AmB1000.1 (Fig 1C). Overexpression of the wild-type copy of gene LinJ.16.1240 in L. infantum
AmB1000.1 had no impact on the resistance phenotype against either AmB or MF (S2 Fig).
This new role of MT in AmB resistance is not limited to L. infantum since selection for AmB
resistance in L. major Friedlin similarly selected for a MT frameshift mutation in mutant L.
major AmB1080.3 (S1 Fig). The mutant displayed a 2-fold cross-resistance to MF (S3A Fig)
and transfection of a wild-type copy of the MT reduced not only resistance to MF, but also to
AmB (3-fold) (S3B Fig).
We also tested the survival of AmB1000.1 and MF200.5 in PMA-differentiated THP-1 mac-
rophages and the role of MT in resistance in intracellular parasites. The PIdx, represented as
the percentage of infected cells multiplied by the mean number of parasites per cell, of L. infan-
tum wild-type parasites was 540 with a mean number of 6.5 amastigotes per macrophage,
while the PIdx for AmB1000.1 and MF200.5 were lowered by half including the number of
amastigotes inside the infected macrophages (Fig 2A). The impaired infectivity was MT-
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related since there was a partial rescue of the phenotype in the AmB1000.1 MT add-back that
reached a PIdx of 420 with 5.5 parasites per macrophage (Fig 2A). The AmB1000.1 intracellular
amastigotes were also resistant to AmB (Fig 2B) and maintained their cross-resistance to MF
(Fig 2C) when compared to wild-type amastigotes. Similar results were found for mutant
MF200.5 that maintained their cross-resistance to AmB inside macrophages (Fig 2B and 2C).
Introducing a wild-type copy of the MT in AmB1000.1 led to a reduction in resistance levels to
both antileishmanial agents (Fig 2B and 2C).
The role of mutations in MT in miltefosine transport
Mutations in MT are often associated with defects in MF transport [16, 17, 40]. Thus, muta-
tions in MT in AmB1000.1 prompted us to probe the ability of the mutant to take up MF. We
monitored the uptake of MT-11C-BODIPY, a fluorescent analogue of MF with in vitro leish-
manicidal activity comparable to that of the original alkyl-phosphocholine [32]. The transport
of MT-11C-BODIPY was greatly impaired in the MF200.5 mutant in comparison to the wild-
type strain (Fig 3). In the mutant AmB1000.1 the decrease in accumulation of the fluorescent
Fig 1. Role of mutations in the miltefosine transporter (MT) in miltefosine and amphotericin B cross-resistance. Dose-response curves with
promastigotes in the presence of AmB (A) and MF (B) for Ldi263 wt (●); MF200.5 (■); AmB1000.1 (▲) mock-transfected parasites; MF200.5+MT (□);
and AmB1000.1+MT (4) add-back cell lines over 72 h. An average of at least three independent biological replicates is shown, with error bars
depicting the standard error of the mean. EC50 values were calculated from the dose-response curves after performing a nonlinear fitting with the
Graphpad 5.0 software program (C). Statistical significance between the mock-transfected wild-type and the rest of the strains was evaluated by
unpaired two-tailed t-test (*p 0.05, **p 0.01, ***p 0.001).
doi:10.1371/journal.pntd.0005171.g001
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Fig 2. Infectivity of the different strains in THP-1-derived macrophages and intracellular drug
resistance. (A) Infectivity of the different studied strains after 96h post-infection in the absence of drug
treatment. The PIdx represents the percentage of infected cells multiplied by the mean number of parasites
per cell. Histogram showing normalized PIdx dose-response effect after 96 h of exposition to increasing
concentrations of AmB (B) and MF (C) for the strains studied in (A). Normalization represents the percent
reduction of the total parasite burden compared to the non-treated infected control. Data are the mean ± S.D.
Miltefosine Transporter in Amphotericin B Resistance
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005171 December 2, 2016 8 / 20
molecule was minimal but statistically significant (Fig 3). The introduction of an episomal
copy of wild-type MT restored MF accumulation in the MF200.5 background whilst
AmB1000.1 experienced a 2.6-fold increase in the amount of MF accumulated (Fig 3). This is
in line with the MF re-sensitization observed for both mutants upon transfection of the rescue
plasmid (Fig 1C).
Changes in lipid-species content in amphotericin B and miltefosine
resistant mutants harbouring mutations in the MT
Mutations in the MT can lead to cross-resistance to MF and AmB but it would appear that dif-
ferent mutations have different outcomes on MF transport (Fig 3). As MT translocates lyso-
phospholipids, we hypothesized that changes in membrane lipid content triggered by muta-
tions in the MT could be responsible for AmB/MF cross-resistance. The lipid/fatty acid com-
position of the mutants AmB1000.1 and MF200.5 were thus assessed and compared to those of
wild-type and add-back cells.
Phospholipids (PLs) content in L. infantum 263 wild-type, MF200.5, AmB1000.1, and
AmB1000.1 MT add-back parasites was analysed by electrospray ionisation-mass spectrometry
(ES-MS). Negative ion ES-MS survey scans (600–1000 m/z) of total lipid extracts revealed sig-
nificant changes in mutants AmB1000.1 (Table 1 and S4C Fig, upper panel) and MF200.5
(Table 1 and S4B Fig, upper panel) compared to wild-type parasites (S4A Fig, upper panel).
We observed that several IPC lipid species from 34:0 to 38:0 were increased in both mutants
(Table 1, S4A–S4C Fig upper panel). Transfection of the MT gene in AmB1000.1 brought back
these IPC species closer to wild-type levels (Table 1). Two of the major PI species at 836 and
850 m/z were decreased in both mutants, probably as a result of increased IPC formation
which requires PI. However, there was also a corresponding increase in the PI 42:8 species
(934 m/z) (Table 1). Transfection of the MT gene in AmB1000.1 brought back the PI species
closer to wild-type levels (Table 1). The PE species were relatively unchanged in MF200.5 and
AmB1000.1 with the notable exceptions of a16:1/19Δ and 16:1/19Δ that were increased in both
mutants (Table 1, S4 Fig upper panels). Again, the transfection of wild-type MT in AmB1000.1
brought back those lipid species closer to wild-type levels (Table 1, S4 Fig upper panels).
The positive ion ES-MS survey scans (600–1000 m/z) of total lipid extracts derived from
both mutants indicated slight variation in individual PC species. We also observed increased
presence of ceramide species at 659 and 685 m/z for mutants MF200.5 (S4B Fig lower panel)
and AmB1000.1 (S4C Fig lower panel). Introducing a wild-type copy of MT in AmB1000.1
reversed to some extent the observed differences (S4D Fig lower panel). The lyso-phospholipid
content as determined by positive and negative ion survey scans (120–600 m/z) showed no sig-
nificant differences between the WT, the resistant strains and the MT add back.
Leishmania PE species often contain the cyclopropyl fatty acid C19Δ [41, 42]. Several PE spe-
cies were identified and confirmed by accurate mass spectrometry (S5 Fig, S3 Table), by parent
ion ES-MS-MS of 295 m/z corresponding to the C19Δ fragment (S6A Fig) and by daughter ion
fragmentation by ES-MS-MS (S6B–S6G Fig). The total fatty acid content, including C19Δ spe-
cies, was determined in wild-type and resistant parasites. Derivatization of the total fatty acid
content into their FAME enabled their quantification by GC-MS. Total ion chromatograms
were obtained from mid log phase parasites for each strain and an example of the fatty acid dis-
tribution profile for wild-type L. infantum strain can be found in S7A and S7B Fig. All FAME
of two independent experiments run in triplicate. Statistical significance between the mock-transfected wild-
type and the rest of the strains was evaluated by unpaired two-tailed t test (*p 0.05, **p 0.01,
***p 0.001).
doi:10.1371/journal.pntd.0005171.g002
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species were identified and their relative percentages calculated (Table 2). Most FAMEs were
similar across all strains, including the relative ratio of saturated and unsaturated fatty acids.
However, both AmB1000.1 and MF200.5 mutants showed a ~4-fold increase in C19Δ. The sec-
ond fatty-acid species altered significantly in both mutants corresponded to fatty acid C24:0,
which was increased by 1.6-fold in AmB1000.1 and MF200.5 (Table 2). Episomal transfection
of a wild-type copy of MT in AmB1000.1 restored both C19Δ and 24:0 fatty acids to near wild-
type levels (Table 2).
Sphingolipids (SL) are major component of Leishmania membranes [41] and Leishmania
do not process the de novo biosynthetic pathways for neither sphingomyelin, nor complex
glyco-SLs [41]. The overall relative abundance of IPCs and PIs, as well as the total amount of
lipid-inositol, were thus determined in mutants AmB1000.1 and MF200.5 and compared to
those of wild-type parasites (Table 3). L. infantum 263 wild-type presented a relative distribu-
tion of 39% IPC and 61% PI of their total lipid containing inositol species. AmB1000.1 and
MF200.5 mutants showed a significant increase in IPC formation, with percentages of 51%-
53% for IPC and 49%-47% for PI, respectively. Interestingly, introduction of the wild-type
copy of the MT in the AmB1000.1 mutant resulted in a shift back of the IPC-PI percentages to
45% -55%, values closer to wild-type parasites. The AmB and MF mutants also showed a sig-
nificant increase in total inositol containing lipids, highlighting the significant increase in IPC
content within these cells. The total inositol-lipid content was returned to wild-type like levels
in the add-back line (Table 3).
Fig 3. Miltefosine transport of drug resistant Leishmania. Histogram showing MF accumulation for the
different strains generated and the wild-type mock-transfected line measured by fluorescence intensity of
parasites treated with 5 μM MT-11C-BODIPY for 1 h. Untreated parasites were used to subtract the
background noise. Data are the mean ± S.D. of three independent experiments run in triplicate. Statistical
significance between the mock-transfected wild-type and the rest of the strains was evaluated by unpaired
two-tailed t test (*p 0.05, ***p 0.001).
doi:10.1371/journal.pntd.0005171.g003
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To complete our analysis of lipids, and because of the suspected mode of action on AmB,
we also measured sterols by GS-MS in AmB1000.1, AmB1000.1+MT, MF200.5 and wild-type
cells (S8 Fig). Levels of sterols in wild-type cells (Table 4) were similar to what observed in
other species [43, 44]. The level of ergosterol and 5-dehydroepisterol were greatly decreased in
AmB1000.1 while 4-methyl-8,24-cholestadienol was strongly increased (S8 Fig; Table 4).
Table 1. Comparison of the lipid PI, IPC and PE species between WT and MF200.5, AmB1000.1 or AmB1000.1+MT. These comparisons are based
upon parent-ion scanning of m/z 241 for PI and IPC (PI 32:0 was used as an internal standard); 35-65V and parent-ion scanning of m/z 196 for PE (PE 28:0
was used as an internal standard). When required parent-ion scanning of m/z 295 for C19Δand accurate mass assisted distinctions between PE species with
the same nominal mass (S6 Fig and S3 Table). The symbols show relative increase or decrease relative to wild-type cells “+++, ++, +, =, -, –, —”.
Observed mass (m/z) Lipid species MF200.5a AmB1000.1a AmB1000.1+MTa
751 IPC 32:1 = = =
753 IPC 32:0 = = =
779 IPC 34:1 ++ ++ +
781 IPC 34:0 +++ ++ +
807 IPC 36:1 +++ ++ +
809 IPC 36:0 +++ ++ +
833 IPC 38:1 = + =
835 IPC 38:0 + ++ =
861 IPC 38:1 = + =
836 PI 34:1 - – –
838 PI 34:0 – - —
848 PI a-36:2 - = =
850 PI a-36:1 – ++ –
852 PI a-36:0 - = -
860 PI 36:3 = = ++
862 PI 36:2 = + +
864 PI 36:1 = + =
866 PI 36:0 = = =
892 PI 38:1 – - +
894 PI 38:0 – - =
934 PI 42:8 +++ +++ =
690 PE 32:0 = – –
698 PE a-34:3 = - -
700 PE a-34:2 = - -
712 PE 34:3 + = =
714 PE 34:2/ PE a-16:1/19Δ =/+ =/= =/=
716 PE 34:1/ PE a-16:0/19Δ =/+ =/+ =/=
726 PE a-36:3 + = =
728 PE a-36:2/16:1/19Δ =/++ =/++ =/-
742 PE 36:2/ a-18:1/19Δ =/= =/+ =/-
744 PE 36:1/ a-18:0/19Δ =/= =/+ =/=
766 PE 38:4 = = =
768 PE 38:3 = = =
770 PE 38:2 = = =
772 PE 38:1 + = =
aSometimes in Table 1 the lipid species share an observed mass (e.g. PE 34:1 and PE a-16:0/19Δwere detected at 716 (m/z)). While the presence of the
first species may remain unaltered with respect to the wild-type, the second one may increase or decrease. The nomenclature =/+, =/++ and =/- was used in
these cases.
doi:10.1371/journal.pntd.0005171.t001
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Surprisingly ergosterol was markedly decreased in MF200.5 as well, but episterol was now the
dominant sterol (S8 Fig; Table 4). In contrast to other lipid species (Tables 1, 2 and 3) transfec-
tion of wild-type MT in AmB1000.1 did not modify the distribution of sterols (S8 Fig, Table 4).
Discussion
Current clinical policies against visceral leishmaniasis in the endemic region of Bihar in India
support the use of sequential treatments relying on administration of liposomal AmB followed
Table 2. Total fatty acid content quantification (relative %). GC-MS was used to determine the fatty acid content of the different L. infantum strains, in
comparison with wild-type parasites. S7 Fig includes an example for total ion chromatogram of derivatised fatty acids from lipid extracts of L. infantum 263
wild-type. Data are the mean of three independent experiments. Statistical significance between the mock-transfected wild-type and the rest of the strains was
evaluated by unpaired two-tailed t test (***p 0.001).
Fatty acid Retention time (min) Relative quantification (%)
WT AmB1000.1 AmB1000.1 +MT MF200.5
14:0 31.2 2.1 2.3 2.6 2.2
16:1 35.3 0.2 0.1 0.1 0.1
16:0 35.6 2.8 2.9 2.9 2.8
18:3 n = 3 38.8 1.1 0.9 0.7 0.9
18:3 n = 6 38.9 1.1 1.0 0.9 0.9
18:2 39.1 28.9 27.9 28.1 28.4
18:1 39.2 24.6 20.3 24.7 19.6
18:0 39.7 19.8 19.0 18.7 19.2
C19Δ 40.8 0.7 4.1*** 0.8 3.8***
20:4 n = 3 42.1 2.9 2.5 2.7 2.7
20:4 n = 6 42.2 2.1 2.1 2.0 2.0
20:3 42.4 0.5 0.2 0.3 0.5
20:2 42.6 3.8 4.0 3.9 4.2
20:1 42.8 0.6 0.4 0.5 0.5
20:0 42.9 0.2 0.1 0.1 0.1
22:6 n-3 44.1 1.8 0.9 1.4 1.7
22:5 n-3 44.2 2.0 1.8 1.7 1.9
22:2 44.7 1.6 1.2 1.6 1.4
24:5 n-6 46.1 1.8 1.9 1.7 1.8
24:4 n-6 46.4 2.7 2.8 2.9 3.5
24:0 48.9 1.7 2.8*** 1.6 2.7***
% Saturated 26.6 27.1 25.7 27.0
% Unsaturated 73.4 72.9 74.3 73.0
doi:10.1371/journal.pntd.0005171.t002
Table 3. IPC/PI ratio and total inositol quantification relative to the wild-type strain. Data are the mean ± s.d. of two independent experiments run in trip-
licate. Statistical significance of INO between the mock-transfected wild-type and the rest of the strains was evaluated by unpaired two-tailed t test (*p 0.05,
**p 0.01, ***p 0.001).
Abundance relative to total INO (%) Total INO relative to WT (%) Abundance relative to WT (%)
Ldi263 wt IPC 39.0 ± 1.4 — —
PI 61.0 ± 1.4 —
AmB1000.1 IPC 51.4 ± 1.0*** 127.3 ± 6.0** 167.5 ± 2.6***
PI 48.6 ± 1.0*** 102.5 ± 2.6
AmB1000.1+MT IPC 44.9 ± 1.1*** 106.2 ± 1.7* 121.1 ± 1.7**
PI 55.1 ± 1.1*** 96.0 ± 1.7
MF200.5 IPC 52.8 ± 1.1*** 116.1 ± 4.6* 156.5 ± 2.4**
PI 47.2 ± 1.1*** 90.5 ± 2.4*
doi:10.1371/journal.pntd.0005171.t003
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by a short 7-days administration of MF [21, 22]. Resistance is not a current threat for AmB
clinical use [5] although L. donovani field strains unresponsive to AmB have been reported [6].
Drug combination treatments involve shorter dosing schedules, which increases compliance
and are less prone to select drug-resistant parasites compared to classical single-drug therapies
[8, 45]. However, the existence of shared resistance mechanisms between two of the main
leishmanicidal agents could lead to treatment failure and emergence of new refractory parasitic
populations. Indeed, it has been recently reported that L. donovani can become resistant to
drug combinations, including the combination of AmB/MF, and that the multi-resistant phe-
notypes are maintained in amastigotes [46]. Similarly, the characterization of several L. dono-
vani field isolates revealed that susceptibility profiles against MF and AmB were positively
correlated, thus identifying a risk for cross-resistance [46]. In this study we demonstrate that
cells selected for AmB can be cross-resistant to MF and the reverse is also true. We also provide
evidence for one pathway of cross-resistance through lipid content modifications, which is
seemingly linked to mutations in the MT. This cross-resistance should lead to careful consider-
ations when sequential treatments are considered in endemic regions [21, 22] especially
because resistance is observed also for intracellular parasites (Fig 2).
The mutations in the MT gene of L. infantum MF200.5 and L. major AmB1080.3 lines are
predicted to be in conserved domains of the MT (S1 Fig), whilst the G433S substitution in the
MT of L. infantum AmB1000.1 is located nearby the DKTGTLT motif of the ATPase phos-
phorylation domain [47]. The lack of a structure for MT renders it difficult to predict the
impact of this mutation on the function of the transporter, but lipid composition is altered and
reintroducing an episomal copy of MT revert in part the mutation phenotype (Tables 1, 2 and
3). Reintroduction of a wild-type copy of MT also reverted resistance to both MF and AmB
(Fig 1), and intracellular survival (Fig 2). Links between mutations in P-type ATPase and the
import of different phospholipid species has been reported in mammalian cells [48–50]. Muta-
tion in MT in MF200.5 is correlated with a decrease in MF uptake (Fig 3) and this likely con-
tributes to MF resistance. In contrast, the uptake of MF is only minimally changed in
AmB1000.1, suggesting that the mutation in MT may lead to MF cross-resistance by another
mechanism. One possibility is that the changes in lipid composition in AmB1000.1 allow for a
higher accumulation of MF within its membrane. Indeed, the AmB1000.1 mutant expressing
wild-type MT through episomes had a susceptibility to MF identical to that of wild-type para-
sites (Fig 1) despite accumulating twice as much MF (Fig 3). Our accumulation experiments
cannot distinguish between genuine intracellular uptake from accumulation of the drug at the
level of the plasma membrane. It is thus possible that lipid-related compensatory mechanisms
developed by AmB1000.1 may lead to less MF intracellular translocation. While the regulatory
subunit Ros3 [7] is not mutated in AmB1000.1, we cannot exclude an impaired expression and
its contribution, if any, to AmB-MF cross-resistance remains to be clarified.
Overexpressing a wild-type version of the MT in AmB1000.1 did not totally reverted its
resistance to AmB and other mechanisms, such as the upregulation of proteins implicated in
protection against drug-induced oxidants [23], should complement the protective effect
achieved through changes in cellular-membrane lipids. For example, the level of sterols is
altered in AmB1000.1 and this is independent of the MT (Table 4). This change in sterol may
contribute to resistance but further work would be required to isolate the genes involved in
those sterol changes. It is salient to point out that AmB1000.1 shows aneuploidy for 6 chromo-
somes (S1 Table) and that many SNPs were detected in its genome, 85 of which were in coding
sequences (S2 Table, S2 and S3 Datasets), and some may have a role in AmB resistance. Besides
resistance, MT-mediated lipid changes may also impact on parasite-macrophage interactions.
As observed here for L. infantum AmB1000.1 and MF200.5, AmB-resistant [11, 51] and MF-
resistant cells [52] had previously been reported to be less infective, suggesting that parasites
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with mutations in the MT may be selected against in the absence of drug pressure. This is not
always the case however, as MF-resistant L. major [52] or L. amazonensis [53] with mutations
in the MT did not show reduced infectivity, and the potential for resistance to multiple drugs
by a single point mutation remains real.
Several studies have pointed to modifications in lipid metabolism as a major factor for both
AmB [11, 54] and MF resistance in Leishmania [13, 14, 19, 20, 40]. Among the lipid species
whose abundances were similarly altered in the AmB1000.1 and MF200.5 mutants is the note-
worthy increase of IPC, PI and 19Δ-containing PE species. Interestingly, preliminary lipid
quantification experiments with the L. major AmB1080.3 mutant revealed variations in both
negative and positive ion ES-MS survey scans (S3C Fig) similar to those found for mutant L.
infantum AmB1000.1 (S4C Fig). A recent study found that L. donovani parasites exposed to
MF exhibit increased levels of three PE species [55], which support our findings regarding the
increased levels of 19Δ-containing PE for both mutants. Interestingly, disruption of the
LdMT-LdRos3 complex in L. donovani was shown to affect the asymmetry of membrane lipids
and resulted in an increased exposure of PE to the exoplasmic leaflet of the plasma membrane
[56]. However, in contrast to our resistant selected lines, these disrupted lines did not show sig-
nificant differences in the total amount of PE and PI [56].
Analysis of FAMEs also confirmed the significant increase of C19Δ for both AmB1000.1
and MF200.5 mutants (Table 2). It has been reported that C19Δ is not abundant in wild-type
L. infantum [36], and since its formation requires a high energy cost [57] it should provide
important survival gain to the parasite. Interestingly, studies in E. coli have shown how cyclo-
propane fatty acids (CFAS)-mediated membrane modifications protect against environmental
stresses (temperature, pH, salt concentration, etc.) [58. 59]. However, the impact of CFAS on
the fluidity of the lipid bilayer is unclear, some studies supporting that defect in CFAS would
result in a decrease of membrane fluidity [60] but others suggesting an enhanced fluidity [61].
In addition to C19Δ, lignoceric acid 24:0 was also increased in both AmB1000.1 and MF200.5
mutants. Lignoceric acid was previously detected in MF-resistant L.-donovani promastigotes
but not in wild-type cells [20].
The content of SLs was also found to be modified in resistant parasites, with IPC being
greatly increased in both mutants (Table 3). This correlates well with the enhanced levels of
d16:0/18:0-IPC identified in MF-treated L. donovani [55]. Complex SLs like IPC are found in
the outer leaflet of plasma membranes together with sterols and contribute to the overall
plasma-membrane fluidity [62]. Moreover, changes in IPC-PI levels, most probably due to PI
being the precursor for IPC formation, may also act as a compensatory effect due to the lack of
Table 4. GC-MS analysis of sterols in Ldi263, MF200.5, AmB1001.1 and AmB1000.1+MT. Data are the mean ± s.d. of three independent experiments.
Relative percentages based upon peak areas. TIC of chromatogram 39.50–43.50 min shown in S8 Fig. ND-not detected.
Label Molecular Ion (m/z) Annotation Relative Percentages
Ldi263 MF200.5 AmB1001.1 AmB1000.1+MT
1 386 Cholesterol 11.0±1.8 10.7±1.6 5.3±0.7 5.2±0.4
2 396 5-dehydroepisterol 68.8±4.2 19.6±2.0 1.3±0.2 1.3±0.1
3 396. Ergosterol 7.8±0.6 trace trace trace
4 382 Cholesta-5,7,24-trienol 12.2±0.8 0.7±0.2 13.9±1.2 12.8±1.5
5 366 Episterol ND 68.2±3.9 ND ND
6 412 14-methyl-fecosterol ND 0.8±0.1 6.6±0.2 7.0±0.2
7 384 Zymosterol ND ND 1.2±0.1 1.1±0.1
8 384 cholesta-7,24-dienol ND ND 7.6±0.3 6.7±0.5
9 398 4-methyl-8,24-cholestadienol ND ND 73.1±6.0 65.9±4.7
doi:10.1371/journal.pntd.0005171.t004
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optimal fatty acid containing diacyl-phospholipids secondary to defective MT activity. This in
turn may also impact upon the PI species available for GPI anchor biosynthesis and usage.
While MT point mutations play a direct role in MF-resistant strains, it seems they can also
induce lipid-content modifications in AmB resistant cells that favour cross-resistance to MF,
most likely by increasing the ability of the parasite to accumulate MF in its membrane rather
than hindering its uptake. This would suggest that resistance to AmB but also cross-resistance
to MF is much likely related to changes in lipid composition and possibly in the intracellular
routing of MF. Different mutations in MT have thus diverse functional consequences on the
transport of MF (Fig 3). These results reinforce and expand the knowledge on the complex
nature of AmB resistance in Leishmania parasites [23, 46, 63], by including a new and unex-
pected character that also triggers MF cross-resistance. This could have significant impact on
the control of this neglected disease.
Supporting Information
S1 Fig. Graphical representation of the different mutations identified in MT for three
Leishmania drug resistant strains. The diagram includes the different conserved protein
domains identified for the MT (GenBank: AAQ82704.1).
(TIF)
S2 Fig. Effect of the transfection of an episomal copy of the wild-type gene LinJ.16.1240 in
the AmB1000.1 mutant background. (A) EC50 determination curves in the presence of
amphotericin B for Ldi263 wt (62.01 ± 5.00 nM), AmB1000.1 (1.97 ± 0.04 μM) and
AmB1000.1+LinJ.16.1240 (1.89 ± 0.11 μM) cell lines over 72 h. (B) EC50 determination curves
in the presence of miltefosine for Ldi263 wt (8.34 ± 0.40 μM), AmB1000.1 (31.50 ± 2.80 μM)
and AmB1000.1+LinJ.16.1240 (29.89 ± 3.03 μM) cell lines over 72 h. An average of at least
three independent biological replicates is shown, with error bars depicting the standard error
of the mean. EC50 values were determined by means of Graphpad Prism5 using non-linear
regression analysis.
(TIF)
S3 Fig. Preliminary study for the characterization of mutant L. major Friedlin
AmB1080.3. (A) EC50 determination curves in the presence of miltefosine for LmF wt+mock
(9.05 ± 0.89 μM), AmB1080.3+mock (54.84 ± 5.30 μM) and AmB1080.3+MT (4.43 ± 0.62 μM)
cell lines over 72 h. (B) EC50 determination curves in the presence of amphotericin B for LmF
wt+mock (0.16 μM ± 0.01), AmB1080.3+mock (1.50 ± 0.07 μM) and AmB1080.3+MT
(0.60 ± 0.02 μM) cell lines over 72 h. An average of at least three independent biological repli-
cates is shown, with error bars depicting the standard error of the mean. EC50 values were
determined by means of Graphpad Prism5 using non-linear regression analysis. (C) Negative
(upper panel) and Positive (lower panel) ion ES-MS survey scans (600–1000 m/z) of total lipid
extracts from mutant L. major Friedlin AmB1080. PEs: phosphatidylethanolamines, IPCs: ino-
sitol-phosphoceramides and PIs: phosphatidylinositols. An example of one of three indepen-
dent biological replicates (which showed similar profiles) is shown.
(TIF)
S4 Fig. Identification of abundance changes to the membrane lipids in AmB- and MF-
resistant parasites. Negative ion ES-MS survey scans (600–1000 m/z) of total lipid extracts
from Ldi263 wt (A upper panel), MF200.5 (B upper panel), AmB1000.1 (C upper panel) and
AmB1000.1+MT (D upper panel). Positive ion ES-MS survey scans (600–1000 m/z) of total
lipid extracts Ldi263 wt (A lower panel), MF200.5 (B lower panel), AmB1000.1 (C lower panel)
and AmB1000.1+MT (D lower panel). PEs: phosphatidylethanolamines, IPCs:
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inositolphosphoceramides and PIs: phosphatidylinositols. The different species identified in
the ES-MS surveys are detailed in the Supplementary S4 Table. An example of one representa-
tive of three independent biological replicates is shown.
(TIF)
S5 Fig. High resolution orbitrap mass spectrometry survey scans (600–1000 m/z) of total
lipid extracts from Ldi263 wt; negative ion mode (A), positive ion mode (B).
(PDF)
S6 Fig. Characterisation of the PE species containing C19Δ in total lipid extracts from
Ldi263 wt. (A) ES-MS/MS parents of 295 m/z (C19Δ acyl fragment) in negative mode (600–
1000 m/z). (B-G) are daughter ion ESI-MS/MS spectra of ions identified in S6A Fig: 716, 730,
744, 774, 788, 802 m/z respectively.
(PDF)
S7 Fig. Example of total ion chromatogram of derivatised fatty acids from lipid extracts of
L. infantum 263 wild-type. (A) Chromatogram including all the FAMES species with reten-
tion times spanning from 26.00 to 50.00 min for mid log phase parasites for each strain
detailed in Table 1. (B) Magnification of the chromatogram for the identification of the spec-
tral peak with a retention time of *40 min corresponding to C19Δ. The identity of C19Δ
FAME was confirmed by retention time and spectral comparison with bacterial FAME stan-
dards, which includes C19Δ.
(PDF)
S8 Fig. GC-MS Sterol Analysis of Leishmania strains. TIC of chromatogram 39.50–43.50
min for (A) Ldi263, (B) MF200.5, (C) AmB1000.1, (D) AmB1000.1+MT. Numbered peaks
refer to Table 4 for identification.
(TIF)
S1 Table. Estimated ploidy for Ldi263AmB1000.1 and its WT parent (Ldi263WT).
(PDF)
S2 Table. SNPs deduced from the sequencing of LdiAmB1000.1 and absent from the
sequencing of its Ldi263WT parent.
(PDF)
S3 Table. Mass spectrometric analysis of phosphatidylethanolamine species containing
cyclopropyl fatty acid in Leishmania infantum.
(PDF)
S1 Dataset. InDels.
(PDF)
S2 Dataset. AmB_SNPs-InCDS-NoSyn-Homozygous.
(PDF)
S3 Dataset. AmB_SNPs-InCDS-NoSyn-Heterozygous.
(PDF)
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